#JapanStock

List of IR information related to "JapanStock".

4,845 IR Posts
5 Companies
20689 days ago Last Updated

Filters

Reset
Period:
Importance:
4845 IR Posts
3070 Jelly Beans Group Co., Ltd.
2026/08/25
Notice of Conclusion of Exclusive Distribution Agency Agreement for the “iHEAL” Brand in Japan

Entered into an exclusive domestic distribution agreement for the Korean femcare brand “iHEAL.” Jelly Beans will serve as the Japanese master distributor, aiming for full-scale sales in the second half of 2027 through direct sales, wholesale, and online channels. Also presenting brand strength, market opportunity, and sales strategy.

3195 Generation Path Co., Ltd.
2026/08/25
Notice Regarding Monthly Sales Performance Compared to the Same Month of the Previous Year for May 2026

Aiming to expand D2C products with growth in the EC marketing business and gross margin improvement, although large deals declined due to AI diffusion, reducing segment profit in EC marketing. Conversely, the product planning-related business achieved substantial growth in revenue and profit driven by contributions from Chinese and Vietnamese subsidiaries. Consolidated operating profit increased significantly, and ordinary profit also rose....

6551 Tsunagu Group Holdings, Inc.
2026/08/25
Q&A Summary for the Second Quarter (Midterm) Financial Results for the Fiscal Year Ending September 2026

While sales decline versus the previous year, growth areas such as OMR and circular hiring are expanding. Expansion of alumni support deployment is progressing, but it takes time for on-site penetration. Demand for foreign worker活躍 support is increasing, but strengthening supply capacity is an issue. The staffing business aims to return to profitability. Shareholder benefit conditions require 500 shares or...

3455 Health Care & Medical Investment Corporation
2026/08/19
Supplementary Explanation Document for the Press Release Dated Today

As part of the issuer's published materials, information such as the notice regarding the issuance and offering of new investment units may be included; however, the main text centers on factual matters and points of caution as supplementary explanations. Financial figures are unknown, and the future policy and capital policy directions may be the main themes.

6316 Maruyama Manufacturing Company
2026/08/10
Q3 2026 Fiscal Year Earnings Summary (Japan GAAP) (Consolidated)

Disclosure of the Q3 2026 fiscal year consolidated earnings summary. Highlights by segment of sales and profits, financial position, and key points of consolidated financial statements. The fiscal period is from October 1, 2025 to December 31, 2025 (YoY comparison information is provided in a separate document) and the cumulative totals through June 30, 2026. Key financial indicators and cash...

8750 Daiichi Life Group Co., Ltd.
2026/08/07
Q1 FY2027 Financial Summary (Japan GAAP, Consolidated)

Consolidated results for the first quarter of the fiscal year ending March 2027 were disclosed. YoY changes for revenue and profit are unknown. However, key indicators are disclosed in the PDF within the "Financial Summary" section. Details by segment and financial items are shown in the respective tables.

7096 Stem Cell Research Institute Co., Ltd.
2026/08/06
Financial Summary for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)

Discloses the consolidated results for the first quarter of the fiscal year ending March 2027. Provides trends in revenue and profits, segment-by-segment status, and changes in financial position. The accounting period is from April 1, 2026 to June 30, 2026; major figures are unknown. Future performance outlook is described in the disclosure material.

1 2 3 404
Scroll to Top